Clinical Trial Update: Docetaxel, Carboplatin, and Bevacizumab in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating docetaxel, carboplatin, and bevacizumab for resectable stage I-III non-small cell lung cancer. The study status is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• CARBOPLATIN (Carboplatin)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: University of California, San Francisco | Conditions: Lung Cancer | Phase 2 | Status: TERMINATED